Play all audios:
Access through your institution Buy or subscribe Nissen SE _ et al_. (2007) Effects of a potent and selective PPAR-α agonist in patients with atherogenic dyslipidemia or
hypercholesterolemia: two randomized controlled trials. _JAMA_ 297: 1362–1373 Fibrates are widely prescribed agonists of transcription factor peroxisome proliferator-activated receptor
(PPAR)-α, and are used to treat patients with atherogenic dyslipidemia. These drugs cause marked decreases in serum triglyceride levels and moderate increases in HDL cholesterol (HDL-C).
Nissen _ et al_. conducted two parallel, multicenter, randomized, double-blind, placebo-controlled trials to determine the safety and efficacy of the novel, highly potent and selective
PPAR-α agonist known as LY518674 in patients with lipid disorders. This is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution
Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full
article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs *
Contact customer support RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Highly potent PPAR-α agonist versus standard therapy in patients with lipid
disorders. _Nat Rev Endocrinol_ 3, 502 (2007). https://doi.org/10.1038/ncpendmet0520 Download citation * Issue Date: July 2007 * DOI: https://doi.org/10.1038/ncpendmet0520 SHARE THIS ARTICLE
Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard
Provided by the Springer Nature SharedIt content-sharing initiative